Information  X 
Enter a valid email address

OKYO Pharma Limited (OKYO)


Thursday 27 January, 2022

OKYO Pharma Limited

Director/PDMR Shareholding

RNS Number : 7746Z
OKYO Pharma Limited
27 January 2022

PDMR Dealing

London and Boston, MA, January 27, 2022  - OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 200,000 ordinary shares of no par value in the market at prices between 5p and 5.5p per share.

The acquisitions increase Mr Cerrone's beneficial interests in the capital of the Company from 52.64% to 52.66%.


Details of PDMR / person closely associated



Gabriele Cerrone


Reason for the notification


Position / status



Initial notification /amendment

Initial notification


Details of the issuer



OKYO Pharma Limited





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted


Description of the financial instrument

Ordinary Shares of no par value


Identification code of the Financial Instrument

ISIN for OKYO Pharma Limited: GG00BD3FV870


Nature of the transaction

Market Purchase


Price(s) and volume(s)

5p - 100,000

5.5p - 100,000


Date of the transaction

26 January 2022


Place of the transaction




OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer

Gabriele Cerrone, Non-Executive Chairman

+44 (0)20 7495 2379




Optiva Securities Limited

Robert Emmet

+44 (0)20 3981 4173




Notes for Editors:

About OKYO

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

About OK-101

OK-101 is a lipidated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immunological cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) Technology to produce a novel long-acting drug candidate for treating DED. OK-101 has been shown to produce anti-inflammatory activity in mouse models of DED and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

About Dry Eye Disease (DED)

Dry eye is a multifactorial disease that results in ocular discomfort and tear film instability that can lead to ocular surface damage. It is often a chronic problem, particularly in older adults, and is expected to become even more prevalent with the aging population and increased use of digital screens such as computers and smart phones. Despite new product approvals, dry eye disease (DED) remains a significant unmet medical need and is one of the leading causes for patient visits to eye care specialists. Novel therapies that improve the signs and symptoms of dry eye disease will be beneficial to dry eye patients.

For further information, please visit the Company's website at .


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t